tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

VRTX Stock Latest News

Vertex Pharmaceuticals initiated with an Outperform at Scotiabank
The FlyVertex Pharmaceuticals initiated with an Outperform at Scotiabank
2h ago
VRTX
Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025
PremiumMarket News
Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025
1d ago
WMT
NVDA
Vertex Pharmaceuticals: Hold Rating Amid High Valuation and Uncertain Growth Prospects Beyond Cystic Fibrosis
PremiumRatings
Vertex Pharmaceuticals: Hold Rating Amid High Valuation and Uncertain Growth Prospects Beyond Cystic Fibrosis
1d ago
VRTX
Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development
PremiumRatings
Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development
2d ago
VRTX
Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating
PremiumRatings
Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating
2d ago
VRTX
Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data
PremiumRatingsCautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data
3d ago
VRTX
Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities
Premium
Ratings
Vertex Pharmaceuticals: Promising Data Amidst Competitive Renal Landscape and Investment Complexities
3d ago
VRTX
Vertex Pharmaceuticals announces updated data from RUBY-3 study of povetacicept
Premium
The Fly
Vertex Pharmaceuticals announces updated data from RUBY-3 study of povetacicept
3d ago
VRTX
Vertex Pharmaceuticals price target lowered to $546 from $553 at UBS
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $546 from $553 at UBS
5d ago
VRTX
Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating
PremiumRatings
Vertex Pharmaceuticals: Strong Revenue Performance and Promising Prospects Justify Buy Rating
5d ago
VRTX
FDA awards second batch of National Priority Vouchers
PremiumThe Fly
FDA awards second batch of National Priority Vouchers
6d ago
GSK
JNJ
Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights
PremiumCompany Announcements
Vertex Pharmaceuticals Q3 2025 Earnings Call Highlights
8d ago
VRTX
Vertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration
PremiumRatingsVertex Pharmaceuticals: Promising IgAN Market Position with Povetacicept’s Superior Efficacy and Patient-Friendly Administration
8d ago
VRTX
Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital
Premium
The Fly
Vertex Pharmaceuticals price target lowered to $415 from $423 at RBC Capital
8d ago
VRTX
Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong CF Business and Promising Pipeline Developments
Premium
Ratings
Optimistic Outlook for Vertex Pharmaceuticals Driven by Strong CF Business and Promising Pipeline Developments
8d ago
VRTX
Vertex Pharmaceuticals price target lowered to $445 from $455 at Stifel
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $445 from $455 at Stifel
8d ago
VRTX
Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion
PremiumRatings
Vertex Pharmaceuticals: Strong Buy Rating Amid Promising Growth and Strategic Expansion
8d ago
VRTX
Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals
PremiumRatings
Vertex Pharmaceuticals: Hold Rating Maintained Amid Mixed Financial Signals
8d ago
VRTX
Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays
PremiumThe Fly
Vertex Pharmaceuticals price target raised to $414 from $408 at Barclays
9d ago
VRTX
Vertex Pharmaceuticals Reports Strong Q3 2025 Results
PremiumCompany AnnouncementsVertex Pharmaceuticals Reports Strong Q3 2025 Results
9d ago
VRTX
Closing Bell Movers: Palantir down 3% after earnings
Premium
The Fly
Closing Bell Movers: Palantir down 3% after earnings
9d ago
FN
GT
Vertex Pharmaceuticals reports Q3 adjusted EPS $4.80, consensus $4.58
Premium
The Fly
Vertex Pharmaceuticals reports Q3 adjusted EPS $4.80, consensus $4.58
9d ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >